Rapid intravenous injection of tobramycin: suggested dosage schedule and concentrations in serum. 1976

A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian

A single, rapid intravenous injection of tobramycin in doses of 1.5 mg/kg or 80 mg administered to subjects with normal renal function produced a wide range of concentrations in serum. Serum concentrations peaked at greater than 20mug/ml in one third of the subjects, but these peaks were transitory. At 6 hr the serum levels were less than 2 mug/ml in all but one subject and were less than 0.1 mug/ml in 50% of the subjects. A dosage interval of 6 hr with a total dosage of 6 mg/kg per day is recommended. The variation in individual dose responses emphasizes the need for monitoring of levels of tobramycin in serum during treatment. Serum concentrations of 4-6 mug/ml 1 hr after injection can be considered indicative of adequate therapy. Levels in serum 6 hr after administration should also be monitored, particularly in the elderly. No immediate or delayed toxic effects were observed after intravenous injection of tobramycin.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin

Related Publications

A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
March 1974, Lancet (London, England),
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
December 1983, European journal of clinical microbiology,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
January 2000, Pediatric pulmonology,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
May 1991, The Journal of antimicrobial chemotherapy,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
June 2020, Pediatric allergy, immunology, and pulmonology,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
January 1969, Medicina experimentalis : International journal of experimental medicine,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
April 1989, The Journal of antimicrobial chemotherapy,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
August 1976, The Journal of infectious diseases,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
April 1980, Antimicrobial agents and chemotherapy,
A P Gillett, and R H Falk, and J Andrews, and R Wise, and V Melikian
December 1983, The Japanese journal of antibiotics,
Copied contents to your clipboard!